Key facts
- This page summarizes Trishna Goswami's Form 4 filing for IN8BIO, INC. (INAB).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 15 Dec 2023, 08:20.
Trishna Goswami - 13 Dec 2023 Form 4 Insider Report for IN8BIO, INC. (INAB)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- INAB
- Reported as of
- 13 Dec 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Dec 2023, 08:20:21 UTC
- Prior SEC filing
- 23 Jun 2023
- Next SEC filing
- 08 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason Minio, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Trishna Goswami filed Form 4 for IN8BIO, INC. (INAB) on 15 Dec 2023.
Change
- Previous filing in this sequence was filed on 23 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INAB
transaction
Common Stock
Award
- Transaction value
- Shares
- +4,098
- Change %
- +156%
- Price
- Shares after
- 6,729
- Date
- 13 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INAB
transaction
Derivative
Series A Warrants (right to buy)
Award
- Transaction value
- Shares
- +4,098
- Change %
- Price
- Shares after
- 4,098
- Date
- 13 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,098
- Exercise price
- $1.25
- Footnotes
- F1, F2
INAB
transaction
Derivative
Series B Warrants (right to buy)
Award
- Transaction value
- Shares
- +4,098
- Change %
- Price
- Shares after
- 4,098
- Date
- 13 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,098
- Exercise price
- $1.50
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported securities are included within 4,098 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 4,098 shares of common stock.
Footnote F2
Fully vested and exercisable.